TSC2 and neoplasm: Since NVP-BEZ235 had effects in inhibiting mTOR, and at low doses could reduce tumor development in this model, we treated a cohort of ENU-treated Tsc2+- mice with NVP-BEZ235 at full dosage, 45 mg/kg PO QD [13], and compared outcome with RAD001 treatment.